Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...